Danlan Beijing Media Limited, Beijing, China.
Positive Alliance, Taipei, Taiwan.
AIDS Behav. 2023 Apr;27(4):1287-1303. doi: 10.1007/s10461-022-03865-5. Epub 2022 Nov 8.
Long-acting injectable regimens for HIV treatment have been developed which are less frequent, more discreet, and more desirable for some people living with HIV (PLHIV) and may help reduce stigma-related barriers to HIV treatment. However, there is little information on the relationship between reported stigma and preference for these newer treatments. We characterized anticipated, experienced, and internalized HIV stigma and examined the associations with treatment preferences among an international sample of PLHIV. Data came from the international, web-based, cross-sectional study called "Positive Perspectives" conducted among PLHIV aged ≥ 18 years in 25 geographic locations during 2019 (n = 2389). Descriptive analyses were stratified among East Asian (n = 230) vs. non-Asian (n = 2159) participants. Results showed that prevalence of anticipated stigma was significantly higher among East Asian than non-Asian participants (72.2%[166/230] vs. 63.8%[1377/2159], p = 0.011). A significantly higher percentage of East Asian (68.7%[158/230]) than non-Asian participants (43.3%[935/2159] indicated that someone finding their HIV pills would cause them much "stress or anxiety" (p < 0.001). Actions taken by some PLHIV to prevent unwanted disclosure included restricting who they shared their HIV status with, hiding their HIV pills, or even skipping a dose altogether because of privacy concerns. Overall, 50.0%[115/230] East Asian participants believed HIV would reduce their lifespan and 43.0%[99/230] no longer planned for their old age because of HIV. Anticipated stigma was strongly associated with receptivity to non-daily regimens. Concerted efforts to reduce stigma and deliver flexible treatment options that address the unmet treatment needs of PLHIV, including confidentiality concerns, may improve their health-related quality of life.
长效注射治疗方案已被开发出来,用于治疗 HIV,这些方案注射频率较低、更隐密,对一些 HIV 感染者(PLHIV)来说更理想,可能有助于减少与 HIV 治疗相关的污名化障碍。然而,关于报告的污名与对这些新治疗方法的偏好之间的关系,信息很少。我们描述了预期的、经历过的和内化的 HIV 污名,并检查了它们与 PLHIV 国际样本中治疗偏好的关联。数据来自于一个名为“积极视角”的国际、基于网络的、横断面研究,该研究于 2019 年在 25 个地理位置的年龄≥18 岁的 PLHIV 中进行(n=2389)。描述性分析按东亚(n=230)和非东亚(n=2159)参与者进行分层。结果显示,东亚参与者预期污名的流行率明显高于非东亚参与者(72.2%[166/230]vs.63.8%[1377/2159],p=0.011)。东亚(68.7%[158/230])参与者比例明显高于非东亚(43.3%[935/2159])参与者,表示发现他们的 HIV 药物会给他们带来“很大的压力或焦虑”(p<0.001)。一些 PLHIV 为防止不必要的披露而采取的行动包括限制与他们分享 HIV 状况的人、隐藏他们的 HIV 药物,甚至因为隐私问题而完全跳过一剂。总的来说,50.0%[115/230]东亚参与者认为 HIV 会缩短他们的寿命,43.0%[99/230]不再因为 HIV 而计划晚年生活。预期污名与接受非每日方案密切相关。共同努力减少污名化,并提供灵活的治疗方案,以满足 PLHIV 的未满足的治疗需求,包括保密性问题,可能会改善他们的健康相关生活质量。